Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed prostate cancer meeting 1 of the following criteria:

- Disease confined to the prostate that is to be treated with radical
prostatectomy after imaging

- Locally advanced disease that is to be treated with radiotherapy

- Patients must agree to undergo surgical pelvic lymph node staging to assist
with determination of radiation fields

- Metastatic disease at initial diagnosis or recurrent or progressive disease

- Patients receive standard of care

PATIENT CHARACTERISTICS:

- WHO performance status 0-2

- Neutrophils ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Hemoglobin ≥ 9.0 g/dL

- Serum bilirubin ≤ 1.5 times upper limit of normal (ULN)

- Serum creatinine ≤ 1.5 times ULN

- Must be registered with the Cancer Research UK Drug Development Office

- Capable of cooperating with imaging procedure and follow-up

- Fertile patients must use effective contraception during and for 6 months after
completion of study therapy

- Not at high medical risk because of non-malignant systemic disease, including active
uncontrolled infection

- No history of recent significant cardiac arrhythmia

- No prior NYHA class III-IV cardiac disease or concurrent congestive heart failure

- No other condition that, in the Investigator's opinion, would not make the patient a
good candidate for the clinical trial

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- No chemotherapy or radiotherapy prior to or within 2 weeks of study therapy

- No prior major thoracic and/or abdominal surgery from which the patient has not yet
recovered

- No other concurrent investigational drugs

- Concurrent anticancer therapy allowed